Aims & Scope


Open Journal of Rheumatology and Autoimmune Diseases is a peer reviewed international journal dedicated to the latest advancements in Rheumatology and Autoimmune Diseases. The goal of this journal is to keep a record of the state-of-the-art research and to promote study, research and improvement within its various specialties.

All manuscripts submitted to OJRA must be previously unpublished and may not be considered for publication elsewhere at any time during OJRA's review period. Generally, accepted papers will appear online within 3 weeks followed by printed hard copy. The journal publishes original papers including but not limited to the following fields:


  • · Aetiology and Pathogenesis
  • · Autoimmune diseases, such as Addison's disease, celiac disease - sprue (gluten-sensitive enteropathy), dermatomyositis, graves disease, hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, pernicious anemia, reactive arthritis, rheumatoid arthritis, sjogren syndrome, systemic lupus erythematosus, type I diabetes
  • · Autoimmune features of infections
  • · Complications,Side effects of medications used to suppress the immune system
  • · Expectations or prognosis
  • · Incidence and risk factors
  • · Laboratory and Radiological Aspects
  • · New therapeutic strategies in the management of autoimmune diseases difficult to treat
  • · Rheumatism, such as rheumatic aortic stenosis, rheumatic fever, rheumatoid arthritis, Rheumatoid lung disease, rheumatoid pneumoconiosis
  • · Signs and tests,include antinuclear antibody tests,autoantibody tests, rheumatoid factor (RF) , CBC, C-reactive protein (CRP), Erythrocyte sedimentation rate (ESR)
  • · Specific conditions, such as antiphospholipid antibody syndrome, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome (ALPS), autoinflammatory diseases, familial mediterranean fever, goodpasture's syndrome, Lambert-Eaton myasthenic syndrome, antiphospholipid syndrome (APS), neuromyelitis optica, paraneoplastic syndromes, Stiff-Person syndrome
  • · The hotspot in all autoimmune diseases
  • · The increasing use of biologic drugs and new biologic drugs in evolution
  • · Treatment and Prophylaxis
  • · Unmet needs in Rheumatology practice
  • · Update on the diagnosis of anti-phospholipid syndrome
  • · Updates on the criteria of diagnosis of seronegative spondyloarthropathies and new management strategies
  • · Updates on the management of vasculitis

  • We are also interested in short papers (letters) that clearly address a specific problem, and short survey or position papers that sketch the results or problems on a specific topic. Authors of selected short papers would be invited to write a regular paper on the same topic for future issues of the OJRA.

    • ADVERTISEMENT